An antibody-drug conjugate (ADC) is a complex molecule designed to target and destroy cancer cells through the transport and delivery of chemotherapy.
Our business development and licensing team looks for opportunities to complement and augment our pipeline where science and value align.
Our One Pipeline strategy enables us to advance bold science, whether it comes from our own labs or from our collaborator’s labs.
We believe great medicines start with great conversations.
With our broad set of global resources, we work alongside our partners to move bold science forward.
We follow the science that helps impact lives. See how we're helping lead the next wave in cancer care.
Our research is helping us lead the next wave of cancer care and strive for a future where cancer is not just treated but cured.
